Baird Financial Group Inc. Has $11.32 Million Holdings in Edwards Lifesciences Corporation $EW

Key Points

• Baird Financial Group Inc. reduced its stake in Edwards Lifesciences Corporation by 12.0%, selling 21,250 shares for a total holding valued at $11.3 million.
• Several institutional investors, including Nuveen LLC and Jennison Associates LLC, have significantly increased their stakes in Edwards Lifesciences, indicating robust interest in the company.
• Edwards Lifesciences reported $0.67 earnings per share for the last quarter, surpassing analyst expectations, with revenue reaching $1.53 billion.

Baird Financial Group Inc. trimmed its position in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 12.0% during the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 156,142 shares of the medical research company's stock after selling 21,250 shares during the quarter. Baird Financial Group Inc.'s holdings in Edwards Lifesciences were worth $11,317,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Allspring Global Investments Holdings LLC lifted its stake in shares of Edwards Lifesciences by 0.5% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company's stock worth $2,170,000 after purchasing an additional 145 shares during the period. Dynamic Advisor Solutions LLC raised its stake in Edwards Lifesciences by 2.4% during the 1st quarter. Dynamic Advisor Solutions LLC now owns 15,506 shares of the medical research company's stock worth $1,124,000 after acquiring an additional 370 shares during the period. Wealth Enhancement Advisory Services LLC grew its holdings in shares of Edwards Lifesciences by 13.5% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 77,016 shares of the medical research company's stock valued at $5,582,000 after purchasing an additional 9,188 shares in the last quarter. United Asset Strategies Inc. grew its holdings in shares of Edwards Lifesciences by 10.4% in the first quarter. United Asset Strategies Inc. now owns 185,571 shares of the medical research company's stock valued at $13,450,000 after purchasing an additional 17,412 shares in the last quarter. Finally, Farther Finance Advisors LLC grew its holdings in shares of Edwards Lifesciences by 390.7% in the first quarter. Farther Finance Advisors LLC now owns 8,808 shares of the medical research company's stock valued at $633,000 after purchasing an additional 7,013 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the sale, the vice president directly owned 22,002 shares of the company's stock, valued at approximately $1,748,278.92. The trade was a 15.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $75.23, for a total transaction of $673,308.50. Following the completion of the transaction, the insider owned 206,900 shares of the company's stock, valued at $15,565,087. This trade represents a 4.15% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 22,014 shares of company stock worth $1,698,844. Corporate insiders own 1.29% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on EW shares. Truist Financial upped their target price on Edwards Lifesciences from $81.00 to $82.00 and gave the company a "hold" rating in a research report on Friday, July 25th. Royal Bank Of Canada upped their target price on Edwards Lifesciences from $85.00 to $89.00 and gave the stock an "outperform" rating in a research note on Friday, July 25th. Citigroup reaffirmed a "buy" rating and set a $95.00 target price (up from $84.00) on shares of Edwards Lifesciences in a research note on Thursday, May 22nd. Wells Fargo & Company upped their target price on Edwards Lifesciences from $84.00 to $88.00 and gave the stock an "overweight" rating in a research note on Thursday, August 7th. Finally, William Blair raised Edwards Lifesciences to a "strong-buy" rating in a research note on Friday, July 25th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Edwards Lifesciences presently has a consensus rating of "Moderate Buy" and a consensus target price of $85.90.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock traded down $0.07 on Friday, reaching $80.89. 2,283,330 shares of the company were exchanged, compared to its average volume of 3,558,037. Edwards Lifesciences Corporation has a 1-year low of $64.00 and a 1-year high of $83.00. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. The firm has a market cap of $47.49 billion, a price-to-earnings ratio of 11.64, a P/E/G ratio of 3.90 and a beta of 1.07. The company's 50-day moving average is $78.77 and its two-hundred day moving average is $75.21.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.05. The business had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company's revenue was up 11.9% compared to the same quarter last year. During the same period last year, the company posted $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, research analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.